Today: 11 June 2026
Citigroup stock jumps to a fresh 52-week high as bank shares lead Wall Street rally
5 January 2026
1 min read

Citigroup stock jumps to a fresh 52-week high as bank shares lead Wall Street rally

New York, Jan 5, 2026, 15:00 EST — Regular session

  • Citigroup shares climb about 4% and notch a new 52-week high.
  • Big U.S. banks lead gains as investors position for the start of earnings season.
  • Focus shifts to U.S. jobs and inflation data this week, then Citi results on Jan. 14.

Citigroup Inc (NYSE: C) shares rose about 4% to $123.44 in afternoon trading on Monday, after touching a 52-week high of $124.05. The stock’s prior close was $118.70.

The move puts Citi in sharper focus ahead of fourth-quarter results on Jan. 14, when the bank plans to issue its financial release around 8 a.m. ET and host a webcast at about 11 a.m. ET. JPMorgan Chase is expected to report a day earlier, on Jan. 13, before the market opens.

Big banks broadly rose on Monday: JPMorgan was up about 3%, Goldman Sachs gained about 4%, Bank of America added roughly 2% and Wells Fargo rose about 1.5%. The S&P 500 financials index climbed 2.7% as investors looked ahead to quarterly reports, and analysts on average expect S&P 500 financial companies to grow earnings 6.7% from a year earlier in the December quarter, Reuters reported. “The mood has been favoring financial stocks in recent days,” said Steve Sosnick, chief market analyst at Interactive Brokers. Reuters

The broader market also rose after a U.S. military strike that captured Venezuelan President Nicolas Maduro, and investors largely reacted calmly outside pockets of the energy market, a Reuters market wrap showed.

Rate expectations remain a swing factor for banks because they shape net interest margin — the spread between what lenders earn on loans and pay on deposits. Traders currently expect two U.S. rate cuts this year, based on LSEG calculations from futures, Reuters reported.

On the charts, Citi has now cleared its previous 52-week high of $122.84 set on Dec. 24, according to market data.

When Citi reports, investors will scrutinize loan-loss provisions — money set aside for potential defaults — as well as fee trends in trading and investment banking. Expense discipline and capital return plans will also be in focus as the bank lays out how it sees 2026 shaping up.

The risk is that the move runs ahead of the facts. A surprise in payrolls or inflation can quickly change how investors price the path for rates, and that can ripple through bank valuations; Citi also has little cushion if earnings show softer net interest income or a pickup in credit costs.

The next catalysts land quickly: the U.S. Employment Situation report for December is due on Jan. 9, followed by the December CPI report on Jan. 13. Citi reports on Jan. 14.

Stock Market Today

  • Corn Prices Dip Ahead of USDA WASDE Report with Mixed Export Data
    June 11, 2026, 10:50 AM EDT. Corn futures fell by 2 to 3 ¼ cents Thursday ahead of the U.S. Department of Agriculture's (USDA) latest WASDE report, which is expected to show a 6 million bushel cut to old crop carryout and a 10 million bushel reduction in new crop stocks. July corn futures settled at $4.19 per bushel, down ½ cent. Export sales data indicated old crop sales between 0.7 and 1.6 million metric tons, while new crop sales ranged from 200,000 to 500,000 metric tons. Brazilian and Argentine corn production estimates increased slightly to 135.8 million and 60.8 million metric tons respectively. Ethanol production and stocks showed minor changes, with ethanol exports rising to 155,000 barrels per day. Traders remain cautious ahead of USDA's official projections on global corn supply.

Latest articles

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

11 June 2026
TOVX soared 74.6% to $0.4252 after Theriva Biologics published Phase 1 VCN-01 data showing survival and biomarker signals in head-and-neck cancer, but the jump was not due to drug approval or revenue; investors face ongoing financing, dilution, and clinical-trial execution risks, with the company’s cash runway only into Q1 2027 and substantial doubt about its ability to continue as a going concern without new capital.
Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

11 June 2026
Trulieve began NYSE trading as TRLV this week after moving from OTC/CSE, authorized a buyback of up to $50 million or 8.5 million shares, and closed its first NYSE session at $11.50, down 0.43%, before trading near $11.78 early Thursday, as investors weigh whether the uplisting and buyback will boost demand amid ongoing federal cannabis policy uncertainty.
Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

11 June 2026
Propanc Biopharma shares soared as much as 392% after authorizing up to $5 million in stock buybacks—exceeding its prior $3.1 million equity value—even as it reported just $443,702 in cash and flagged going-concern risks, with investors now focused on whether its lead cancer drug PRP will advance to a planned Phase 1b trial this year.
NuScale Power stock jumps 16% as House sets ‘New Nuclear Era’ hearing — what’s next for SMR
Previous Story

NuScale Power stock jumps 16% as House sets ‘New Nuclear Era’ hearing — what’s next for SMR

3.5 million hit by University of Phoenix data breach as school rolls out “credit for prior learning” push
Next Story

3.5 million hit by University of Phoenix data breach as school rolls out “credit for prior learning” push

Go toTop